| 1 |
陈敏华, 严昆, 戴莹, 等. 肝超声造影应用指南(中国)(2012年修改版) [J]. 中华超声影像学杂志, 2013, 22(8): 696-722.
|
| 2 |
Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS [J]. Ultrasound Med Biol, 2013, 39(2): 187-210.
|
| 3 |
Albrecht T, Blomley M, Bolondi L, et al. Guidelines for the use of contrast agents in ultrasound-January 2004 [J]. Ultraschall Med, 2004, 25(4): 249-256.
|
| 4 |
Hyvelin JM, Gaud E, Costa M, et al. Characteristics and echogenicity of clinical ultrasound contrast agents: an in vitro and in vivo comparison study [J]. J Ultrasound Med, 2017, 36(5): 941-953.
|
| 5 |
Numata K, Fukuda H, Miwa H, et al. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma [J]. Eur J Radiol, 2014, 83(1): 95-102.
|
| 6 |
Bouakaz A, de Jong N. WFUMB safety symposium on echo-contrast agents: nature and types of ultrasound contrast agents [J]. Ultrasound Med Biol, 2007, 33(2): 187-196.
|
| 7 |
郭辉, 刘隆忠, 郑玮, 等. SonoVue与Sonazoid高频条件下对兔肝显像效果的对比分析 [J]. 中华超声影像学杂志, 2011, 20(4): 344-347.
|
| 8 |
郭辉, 李安华, 刘隆忠, 等. 高频条件下(7MHz)SonoVue与Sonazoid剂量变化对兔肝造影效能的比较 [J/CD]. 中华医学超声杂志(电子版), 2011, 8(3): 482-489.
|
| 9 |
Wassef NM, Alving CR. Complement-dependent phagocytosis of liposomes [J]. Chem Phys Lipids, 1993, 64(1-3): 239-248.
|
| 10 |
Yanagisawa K, Moriyasu F, Miyahara T, et al. Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells [J]. Ultrasound Med Biol, 2007, 33(2): 318-325.
|
| 11 |
Toft KG, Hustvedt SO, Hals PA, et al. Disposition of perfluorobutane in rats after intravenous injection of Sonazoid [J]. Ultrasound Med Biol, 2006, 32(1): 107-114.
|
| 12 |
Landmark KE, Johansen PW, Johnson JA, et al. Pharmacokinetics of perfluorobutane following intravenous bolus injection and continuous infusion of sonazoid in healthy volunteers and in patients with reduced pulmonary diffusing capacity [J]. Ultrasound Med Biol, 2008, 34(3): 494-501.
|
| 13 |
Li P, Hoppmann S, Du P, et al. Pharmacokinetics of perfluorobutane after intra-venous bolus injection of sonazoid in healthy chinese volunteers [J]. Ultrasound Med Biol, 2017, 43(5): 1031-1039.
|
| 14 |
Moriyasu F, Itoh K. Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial [J]. AJR Am J Roentgenol, 2009, 193(1): 86-95.
|
| 15 |
Chou YH, Liang JD, Wang SY, et al. Safety of perfluorobutane (Sonazoid) in characterizing focal liver lesions [J]. J Med Ultrasound, 2019, 27(2): 81-85.
|
| 16 |
Lee JY, Minami Y, Choi BI, et al. The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using Sonazoid [J]. Ultrasonography, 2020, 39(3): 191-220.
|
| 17 |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版) [J]. 临床肝胆病杂志, 2020, 36(2): 277-292.
|
| 18 |
Shagdarsuren B, Tamai H, Shingaki N, et al. Contribution of contrast‐enhanced sonography with perfluorobutane microbubbles for diagnosis of recurrent hepatocellular carcinoma [J]. J Ultrasound Med, 2016, 35(7): 1383-1391.
|
| 19 |
Suzuki K, Okuda Y, Ota M, et al. Diagnosis of hepatocellular carcinoma nodules in patients with chronic liver disease using contrast-enhanced sonography: usefulness of the combination of arterial-and kupffer-phase enhancement patterns [J]. J Ultrasound Med, 2015, 34(3): 423-433.
|
| 20 |
Maruyama H, Sekimoto T, Yokosuka O. Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience [J]. J Gastroenterol, 2016, 51(5): 421-433.
|
| 21 |
Kim TK, Hyun-Jung. Contrast-enhanced ultrasound in the diagnosis of nodules in liver cirrhosis [J]. World J Gastroenterol, 2014, 20(13): 3590-3596.
|
| 22 |
Tochio H, Tamaki E, Imai Y, et al. CD68-positive cells in hepatic angiomyolipoma [J]. Oncology, 2017, 92 Suppl 1: 35-39.
|
| 23 |
Dietrich CF, Nolse CP, Barr RG, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2020-WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS [J]. Ultrasound Med Biol, 2020, 46(10): 2579-2604.
|
| 24 |
Wu M, Li L, Wang J, et al. Contrast-enhanced US for characterization of focal liver lesions: a comprehensive meta-analysis [J]. Eur Radiol, 2018, 28(5): 2077-2088.
|
| 25 |
Ohama H, Imai Y, Nakashima O, et al. Images of Sonazoid-enhanced ultrasonography in multistep hepatocarcinogenesis: comparison with Gd-EOB-DTPA-enhanced MRI [J]. J Gastroenterol, 2014, 49(6): 1081-1093.
|
| 26 |
Korenaga K, Korenaga M, Furukawa M, et al. Usefulness of Sonazoid contrast-enhanced ultrasonography for hepatocellular carcinoma: comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images [J]. J Gastroenterol, 2009, 44(7): 733-741.
|
| 27 |
Hatanaka K, Kudo M, Minami Y, et al. Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT [J]. Oncology, 2008, 75 Suppl 1: 42-47.
|
| 28 |
Ando Y, Ishigami M, Ishizu Y, et al. Utility of contrast-enhanced ultrasonography with perflubutane in evaluating indications for diagnostic percutaneous tumor biopsy in a case of hepatic sclerosed hemangioma [J]. Clin J Gastroenterol, 2018, 11(6): 514-520.
|
| 29 |
Lee J, Jeong WK, Lim HK, et al. Focal nodular hyperplasia of the liver: contrast‐enhanced ultrasonographic features with Sonazoid [J]. J Ultrasound Med, 2018, 11(6): 514-520.
|
| 30 |
Sugimoto K, Moriyasu F, Saito K, et al. Kupffer-phase findings of hepatic hemangiomas in contrast-enhanced ultrasound with Sonazoid [J]. Ultrasound Med Biol, 2014, 40(6): 1089-1095.
|
| 31 |
Kudo M. Breakthrough imaging in hepatocellular carcinoma [J]. Liver Cancer, 2016, 5(1): 47-54.
|
| 32 |
Minami Y, Kudo M. Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma [J]. World J Gastroenterol, 2011, 17(45): 4952-4959.
|
| 33 |
Park JH, Park MS, Lee SJ, et al. Contrast-enhanced US with perfluorobutane for hepatocellular carcinoma surveillance: a multicenter diagnostic trial (SCAN) [J]. Radiology, 2019, 292(3): 638-646.
|
| 34 |
Jang HJ, Kim TK, Burns PN, et al. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation [J]. Radiology, 2007, 244(3): 898-906.
|
| 35 |
Kudo M, Hatanaka K, Maekawa K. Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma [J]. Oncology, 2010, 78(Suppl.1): 40-45.
|
| 36 |
Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy [J]. Oncology, 2008, 75(Suppl.1): 1-12.
|
| 37 |
付甜甜, 丁红. 超声造影在肝细胞癌非手术治疗疗效评估中的应用 [J/CD]. 中华医学超声杂志(电子版), 2018, 15(1): 10-13.
|
| 38 |
Minami Y, Kudo M, Chung H, et al. Contrast harmonic sonography-guided radiofrequency ablation therapy versus B-mode sonography in hepatocellular carcinoma: prospective randomized controlled trial [J]. Ajr Am J Roentgenol, 2007, 188(2): 489-494.
|
| 39 |
Arita J, Takahashi M, Hata S, et al. Usefulness of contrast-enhanced intraoperative ultrasound using Sonazoid in patients with hepatocellular carcinoma [J]. Ann Surg, 2011, 254(6): 992-999.
|
| 40 |
Choi D, Kim PY, Rhim H, et al. Planning ultrasound for percutaneous radiofrequency ablation to treat small (≤3 cm) hepatocellular carcinomas detected on computed tomography or magnetic resonance imaging: a multicenter prospective study to assess factors affecting ultrasound visibility [J]. J Vasc Interv Radiol, 2012, 23(5): 627-634.
|
| 41 |
Miwa H, Numata K, Sugimori K, et al. Differential diagnosis of solid pancreatic lesions using contrast-enhanced three-dimensional ultrasonography [J]. Abdom Imaging, 2014, 39(5): 988-999.
|
| 42 |
Miwa H, Numata K, Sugimori K, et al. Differential diagnosis of gallbladder polypoid lesions using contrast-enhanced ultrasound [J]. Abdom Radiol, 2019, 44(4): 1367-1378.
|
| 43 |
Sidhu P, Cantisani V, Dietrich C, et al. The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in non-hepatic applications: Update 2017 (Short Version) [J]. Ultraschall Med, 2018, 39(2): 154-180.
|
| 44 |
梁舒媛, 罗渝昆, 费翔, 等. 高帧频超声造影在鉴别浅表淋巴结性质中的应用 [J/CD]. 中华医学超声杂志(电子版), 2020, 17(9): 841-847.
|
| 45 |
Nakamura K, Sasaki N, Yoshikawa M, et al. Quantitative contrast-enhanced ultrasonography of canine spleen [J]. Vet Radiol Ultrasound, 2009, 50(1): 104-108.
|
| 46 |
Bertelsen C, King KG, Swanson M, et al. Contrast-enhanced ultrasound with perflubutane for sentinel lymph node mapping in cutaneous melanoma: a pilot study [J]. Laryngoscope, 2019, 129(5): 1117-1122.
|
| 47 |
Tatekawa Y. An intrapancreatic accessory spleen presenting as a rapidly growing pancreatic mass after splenectomy in a patient with hereditary spherocytosis: a case report and literature review [J]. J Surg Case Rep, 2018, 2018(2): rjy029.
|
| 48 |
Shimazu K, Ito T, Uji K, et al. Identification of sentinel lymph nodes by contrast‐enhanced ultrasonography with Sonazoid in patients with breast cancer: a feasibility study in three hospitals [J]. Cancer Medicine, 2017, 6(8): 1915-1922.
|